Dermira, Inc. (DERM) Posts Earnings Results, Misses Expectations By $0.04 EPS
Dermira, Inc. (NASDAQ:DERM) announced its quarterly earnings data on Monday. The biopharmaceutical company reported ($0.93) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.89) by $0.04, Bloomberg Earnings reports. The firm had revenue of $1.07 million for the quarter, compared to the consensus estimate of $1 million.
Dermira (DERM) traded down 14.45% during mid-day trading on Tuesday, hitting $22.15. 1,021,300 shares of the stock were exchanged. Dermira has a 52-week low of $22.04 and a 52-week high of $38.75. The stock’s market cap is $919.69 million. The stock has a 50 day moving average of $29.16 and a 200-day moving average of $30.96.
TRADEMARK VIOLATION WARNING: “Dermira, Inc. (DERM) Posts Earnings Results, Misses Expectations By $0.04 EPS” was posted by Daily Political and is owned by of Daily Political. If you are reading this news story on another website, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The legal version of this news story can be read at https://www.dailypolitical.com/2017/08/08/dermira-inc-derm-posts-earnings-results-misses-expectations-by-0-04-eps.html.
A number of equities research analysts recently commented on DERM shares. Mizuho lowered their price target on shares of Dermira from $42.00 to $40.00 and set a “buy” rating for the company in a report on Thursday, May 25th. BidaskClub lowered shares of Dermira from a “buy” rating to a “hold” rating in a report on Monday, July 3rd. Evercore ISI started coverage on shares of Dermira in a report on Thursday, June 29th. They set an “outperform” rating and a $48.00 price target for the company. Cantor Fitzgerald started coverage on shares of Dermira in a report on Thursday, June 22nd. They issued an “overweight” rating and a $45.00 price objective for the company. Finally, Needham & Company LLC restated a “buy” rating and issued a $46.00 price objective on shares of Dermira in a report on Tuesday, July 18th. Five investment analysts have rated the stock with a sell rating and six have assigned a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $43.80.
In other Dermira news, insider Eugene A. Bauer sold 2,500 shares of the business’s stock in a transaction dated Tuesday, June 20th. The shares were sold at an average price of $30.01, for a total value of $75,025.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Christopher M. Griffith sold 1,312 shares of the business’s stock in a transaction dated Monday, May 15th. The stock was sold at an average price of $27.07, for a total transaction of $35,515.84. The disclosure for this sale can be found here. Insiders sold 16,812 shares of company stock valued at $482,231 over the last quarter. 13.30% of the stock is currently owned by corporate insiders.
Dermira Company Profile
Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.
Receive News & Ratings for Dermira Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira Inc. and related companies with MarketBeat.com's FREE daily email newsletter.